Open AccessDrug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance
Author(s) -
Tomohito Wakabayashi,
Takahiro Nakatsuji,
Hiroko Kambara,
Iku Niinomi,
Saki Oyama,
Ayaka Inada,
Sayaka Ueno,
Mayako Uchida,
Kazunori Iwanaga,
Takatoshi Iida,
Keiko Hosohata
Publication year - 2022
Publication title -
current reviews in clinical and experimental pharmacology
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2772-4336
pISSN - 2772-4328
DOI - 10.2174/1574884716666210215104540
Subject(s) - zanamivir , medicine , oseltamivir , pharmacovigilance , adverse event reporting system , adverse effect , neuraminidase , odds ratio , postmarketing surveillance , neuraminidase inhibitor , confidence interval , drug , adverse drug reaction , pharmacology , immunology , disease , virus , covid-19 , infectious disease (medical specialty)
Several studies reported that abnormal behavior was noted in pediatric patients receiving several drugs, including neuraminidase inhibitors (NIs). However, the information on drugs associated with abnormal behavior in a real-world setting remains limited. The purpose of this study was to clarify the drugs associated with abnormal behavior using a spontaneous reporting system database.